All In Biotech

Drug Trial Radar · NCT03491462

Arimoclomol in Amyotropic Lateral Sclerosis

A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral Sclerosis

Last checked: Nov 19, 2026Latest source record: Aug 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 245 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

245

Actual

Start

Jul 31, 2018

Primary completion

Dec 18, 2020

Study completion Dec 18, 2020

Sponsor

Lead sponsor
ZevraDenmarkIndustry
Sponsor type
Industry
First posted
Apr 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of arimoclomol in amyotropic lateral sclerosis (ALS)

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • ArimoclomolDrug

    2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily

  • PlaceboDrug

    2 matched placebo capsules taken 3 times daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Combined Assessment of Function and Survival (CAFS)Time frame: Over 76 Weeks

Locations

29 sites in 12 countries. Site status is shown where the registry gives one.

  • St. Joseph's Hospital and Medical Center (SJHMC) - Barrow Neurological Institute (BNI) - The Gregory W. Fulton ALS and Neuromuscular Disease Center

    Phoenix, Arizona

  • HonorHealth Neurology

    Phoenix, Arizona

  • UC Irvine Health ALS and Neuromuscular Center

    Orange, California

  • University of Miami

    Miami, Florida

  • University of Kansas Medical Center (KUMC) - Landon Center on Aging

    Kansas City, Kansas

  • Hospital for Special Surgery

    New York, New York

  • Providence Brain & Spine Institute

    Portland, Oregon

  • University of Pensylvania, Perelman Center for Advanced Medicine - Penn Neuroscience Center

    Philadelphia, Pennsylvania

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • University of Virginia Health System

    Charlottesville, Virginia

  • Catholic University Leuven

    Leuven, Belgium

  • London Health Sciences Centre

    London, Ontario, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada

  • Montreal Neurological Institute and Hospital

    Montreal, Quebec, Canada

  • Centre Hospitalier Regional Universitaire (CHRU) Montpellier - Hopital Gui De Chauliac

    Montpellier, France

  • Groupe Hospitalier Pitie-Salpetriere - Centre d'Investigation Clinique Neurosciences 1422

    Paris, France

  • Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum (CVK) - Ambulanz fuer ALS und andere Motoneuronenerkrankungen

    Berlin, Germany

  • Medizinische Hochschule Hannover (MHH) - Klinik fuer Neurologie

    Hanover, Germany

  • Universitaetsklinikum Ulm - Klinik fuer Neurologie

    Ulm, Germany

  • Instituti Clinica Scientifici Maugeri - IRCCS

    Milan, Italy

  • Azienda Ospedaliero Universitaria (AUO) di Torino - Citta'della Salute e della Scienza di Torino

    Torino, Italy

  • University Medical Center Utrecht

    Utrecht, Netherlands

  • Centrum Medyczne NeuroProtect

    Warsaw, Poland

  • Citi Clinic

    Warsaw, Poland

  • Hospital Universitario Vall d'Hebron ALS Unit. Consultas Externas; Office: 9-10-11

    Barcelona, Spain

  • Hospital Carlos III - Hospital Universitario La Paz, ALS Unit

    Madrid, Spain

  • Umeå University Hospital

    Umeå, Sweden

  • Kantonsspital St.Gallen, Muskelzentrum/ALS Clinic

    Sankt Gallen, Switzerland

  • Leonard Wolfson Experimental Neurology Centre

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.